Stroma Medical — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Stroma Medical is pioneering a novel cosmetic ophthalmology procedure for permanent eye color change using a proprietary laser system. The company targets a significant global consumer market of individuals with dark eyes seeking lighter-colored irises, with procedures performed by certified ophthalmologists. As a clinical-stage, pre-revenue entity, Stroma's success hinges on regulatory approvals, physician adoption, and demonstrating long-term safety and efficacy. Its business model involves leasing the Strōma Laser System to established refractive surgery practices worldwide.

Ophthalmology

Technology Platform

Patented laser system designed to fragment and remove the superficial melanin pigment layer of the iris, revealing the underlying stromal color for permanent cosmetic eye color change.

Opportunities

The company addresses a large, untapped global consumer market for cosmetic enhancement, with survey data indicating strong interest.

Its asset-light leasing model to established refractive surgeons allows for rapid scalability and high margins if adopted.

First-mover advantage in a novel niche of aesthetic ophthalmology could establish a dominant market position.

Risk Factors

The primary risk is regulatory approval, as health authorities may demand extensive long-term safety data for this permanent ocular procedure.

Significant unproven medical risks include potential for glaucoma, chronic inflammation, or light sensitivity.

Market adoption is uncertain, as survey interest may not convert to actual demand, and ophthalmologists may be reluctant to offer a purely cosmetic treatment.

Competitive Landscape

Stroma appears to be a first-mover in the space of *permanent*, laser-based cosmetic iris color change. Potential competition could arise from other medical device companies developing similar laser technologies or from cosmetic iris implants, which are highly controversial and associated with severe complications. The company's main competition in the near term is likely the status quo: colored contact lenses.

More companies in Drug Delivery & Formulation →More companies in United States →